Every 424B that Calidi Biotherapeutics, Inc. (CLDI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CLDI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLDI filings page.
Calidi Biotherapeutics, Inc. (CLDI) is conducting a registered direct offering of 1,025,640 shares of common stock at $1.17 per share, for gross proceeds of $1.2 million and estimated net proceeds of about $1.1 million. Shares outstanding will increase from 2,660,209 to 3,685,849 shares immediately after the offering. The company plans to use the cash for working capital and general corporate purposes, including advancing its preclinical and clinical programs.
Calidi is a clinical-stage biotechnology company developing oncolytic virus platforms (RedTail, SuperNova, NeuroNova) and expects to enter the clinic with CLD-401 in early 2027. It reported a $8.3 million net loss for the six months ended June 30, 2026 and an accumulated deficit of $149.9 million, and its auditors and management disclose substantial doubt about its ability to continue as a going concern. The company believes existing cash plus this raise will fund operations for roughly two months under its current plan, so it anticipates needing substantial additional capital, which could be dilutive.
Calidi Biotherapeutics, Inc. is offering up to 703,731 Common Stock Units in a firm‑commitment underwriting, each Unit priced at $0.50 and consisting of one share of Common Stock plus three series warrants (Series J, K and L). The offering also permits up to 9,815,900 Pre‑Funded Warrant Units to avoid >4.99% beneficial ownership limits.
The Units carry Common Warrants exercisable at $0.50 with varying terms (Series J: 5 years; Series K: 1 year; Series L: 6 months) and reset mechanics after the 45th calendar day. Net proceeds are estimated at approximately $4.5 million (before over‑allotment) to be used for working capital and general corporate purposes. The prospectus notes a going concern qualification and preliminary unaudited year‑end cash of $5.6 million.
Calidi Biotherapeutics, Inc. is conducting a firm-commitment public offering of Common Stock Units and, for certain purchasers, Pre-Funded Warrant Units, each unit including one share (or pre-funded warrant in lieu of a share) and one each of Series J, Series K and Series L warrants.
The Common Warrants include reset provisions at the 45th calendar day and after a reverse split approved and effective during fiscal 2026; exercise limitations include a 4.99% beneficial ownership cap (expandable to 9.99% at holder election). The company notes a 1-for-12 reverse stock split effected August 4, 2025 and lists NYSE American symbol CLDI. Management discloses substantial doubt about the company’s ability to continue as a going concern and preliminary cash of $5.6 million as of December 31, 2025.